BR112012015499A2 - método de tratamento de fibrilação atrial - Google Patents
método de tratamento de fibrilação atrialInfo
- Publication number
- BR112012015499A2 BR112012015499A2 BR112012015499A BR112012015499A BR112012015499A2 BR 112012015499 A2 BR112012015499 A2 BR 112012015499A2 BR 112012015499 A BR112012015499 A BR 112012015499A BR 112012015499 A BR112012015499 A BR 112012015499A BR 112012015499 A2 BR112012015499 A2 BR 112012015499A2
- Authority
- BR
- Brazil
- Prior art keywords
- atrial fibrillation
- treatment method
- atrial
- fibrillation treatment
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"método de tratamento de fibrilação atrial" a presente invenção está relacionada a um método para o tratamento ou prevenção de fibrilação atrial e/ou flutter atrial que compreende a co-administração de uma quantidade sinergicamente terapêutica de dronedarona ou de um sal ou sais farmaceuticamente aceitáveis desta e uma quantidade sinergicamente terapêutica de ranolazina ou de um sal ou sais farmaceuticamente aceitáveis desta. também são fornecidos métodos para modulação do ritmo e da frequência ventricular e atrial. essa invenção também está relacionada às formulações farmac~euticas que são adequadas a esta administração combinada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28873909P | 2009-12-21 | 2009-12-21 | |
PCT/US2010/061257 WO2011084733A1 (en) | 2009-12-21 | 2010-12-20 | Method of treating atrial fibrillation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012015499A2 true BR112012015499A2 (pt) | 2016-05-03 |
Family
ID=43736345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012015499A BR112012015499A2 (pt) | 2009-12-21 | 2010-12-20 | método de tratamento de fibrilação atrial |
Country Status (37)
Country | Link |
---|---|
US (3) | US8513254B2 (pt) |
EP (2) | EP2515900B1 (pt) |
JP (2) | JP5723889B2 (pt) |
KR (2) | KR20120107995A (pt) |
CN (3) | CN102665713B (pt) |
AP (1) | AP3536A (pt) |
AR (1) | AR079552A1 (pt) |
AU (1) | AU2010339753B2 (pt) |
BR (1) | BR112012015499A2 (pt) |
CA (1) | CA2784028C (pt) |
CL (1) | CL2012001597A1 (pt) |
CR (1) | CR20120353A (pt) |
CY (1) | CY1116511T1 (pt) |
DK (1) | DK2515900T3 (pt) |
EA (2) | EA025445B1 (pt) |
EC (1) | ECSP12012004A (pt) |
ES (2) | ES2540093T3 (pt) |
HK (1) | HK1170675A1 (pt) |
HR (1) | HRP20150644T1 (pt) |
HU (1) | HUE026916T2 (pt) |
IL (1) | IL220152A (pt) |
ME (1) | ME02179B (pt) |
MX (2) | MX2012007052A (pt) |
NO (1) | NO2749282T3 (pt) |
NZ (2) | NZ627181A (pt) |
PE (1) | PE20121520A1 (pt) |
PL (2) | PL2749282T3 (pt) |
PT (2) | PT2749282T (pt) |
RS (1) | RS54118B1 (pt) |
SG (3) | SG181541A1 (pt) |
SI (2) | SI2515900T1 (pt) |
SM (1) | SMT201500171B (pt) |
TW (1) | TWI508726B (pt) |
UA (1) | UA109887C2 (pt) |
UY (1) | UY33119A (pt) |
WO (1) | WO2011084733A1 (pt) |
ZA (1) | ZA201204608B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4546824B2 (ja) | 2002-05-21 | 2010-09-22 | ギリアード・パロ・アルト・インコーポレイテッド | 糖尿病を処置する方法 |
AU2010276537B2 (en) | 2009-07-27 | 2015-04-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
EP3760180A3 (en) | 2009-07-29 | 2021-01-20 | ICU Medical, Inc. | Fluid transfer devices and methods of use |
WO2011135582A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
TWI510480B (zh) | 2011-05-10 | 2015-12-01 | Gilead Sciences Inc | 充當離子通道調節劑之稠合雜環化合物 |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (pt) | 2011-07-01 | 2018-04-28 | ||
WO2013112932A1 (en) * | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
WO2014179764A1 (en) * | 2013-05-03 | 2014-11-06 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
AU2014296378B2 (en) * | 2013-08-02 | 2017-03-30 | Gilead Sciences, Inc. | Pharmaceutical compositions of ranolazine and dronedarone |
WO2015073922A2 (en) | 2013-11-15 | 2015-05-21 | Northwestern University | Inhibition of oxidative stress in atrial fibrillation |
US9416128B2 (en) | 2013-12-19 | 2016-08-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
CN104951870B (zh) * | 2015-06-01 | 2018-11-13 | 南通科瑞斯生物医药科技有限公司 | 药物临床前心脏风险评估方法 |
WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
JP2019510752A (ja) | 2016-03-04 | 2019-04-18 | ギリアード サイエンシーズ, インコーポレイテッド | オートタキシン阻害剤の組成物及び合剤 |
US10575744B2 (en) | 2017-02-24 | 2020-03-03 | Medtronic Cryocath Lp | Pericardial balloon mapping |
US10799703B2 (en) * | 2017-12-22 | 2020-10-13 | Medtronic, Inc. | Evaluation of his bundle pacing therapy |
EP3530182B1 (en) * | 2018-02-27 | 2020-12-09 | Nokia Technologies Oy | Apparatus and method for determining a change in left ventricular twist of a subject's heart |
US11865186B2 (en) * | 2019-01-24 | 2024-01-09 | Northwestern University | Gene therapy treatment of atrial fibrillation |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
ATE223218T1 (de) | 1989-06-23 | 2002-09-15 | Syntex Llc | Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur |
FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
FR2764800B1 (fr) | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
WO2002009761A2 (en) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
FR2817750B1 (fr) | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
DE60117857D1 (de) | 2000-12-27 | 2006-05-04 | Genzyme Corp | Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen |
WO2003009839A1 (en) * | 2001-07-20 | 2003-02-06 | Karo Bio Ab | Benzofuranes and their use in the treatment of atrial fibrillation |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
JP2008526879A (ja) | 2005-01-06 | 2008-07-24 | シーブイ・セラピューティクス・インコーポレイテッド | ラノラジンを含有する徐放性薬学的処方物 |
WO2007053610A2 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
CA2678272A1 (en) * | 2007-02-13 | 2008-10-02 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
JP2012502047A (ja) | 2008-09-04 | 2012-01-26 | ギリアード サイエンシーズ, インコーポレイテッド | 心房細動を治療する方法 |
-
2010
- 2010-12-16 TW TW099144230A patent/TWI508726B/zh not_active IP Right Cessation
- 2010-12-20 PT PT141613000T patent/PT2749282T/pt unknown
- 2010-12-20 UA UAA201208208A patent/UA109887C2/uk unknown
- 2010-12-20 ME MEP-2015-113A patent/ME02179B/me unknown
- 2010-12-20 CN CN201080058336.3A patent/CN102665713B/zh not_active Expired - Fee Related
- 2010-12-20 BR BR112012015499A patent/BR112012015499A2/pt not_active IP Right Cessation
- 2010-12-20 WO PCT/US2010/061257 patent/WO2011084733A1/en active Application Filing
- 2010-12-20 NZ NZ627181A patent/NZ627181A/en not_active IP Right Cessation
- 2010-12-20 SG SG2012041638A patent/SG181541A1/en unknown
- 2010-12-20 SI SI201030949T patent/SI2515900T1/sl unknown
- 2010-12-20 EP EP20100798436 patent/EP2515900B1/en active Active
- 2010-12-20 NZ NZ600718A patent/NZ600718A/en not_active IP Right Cessation
- 2010-12-20 DK DK10798436.1T patent/DK2515900T3/en active
- 2010-12-20 NO NO14161300A patent/NO2749282T3/no unknown
- 2010-12-20 MX MX2012007052A patent/MX2012007052A/es active IP Right Grant
- 2010-12-20 AR ARP100104774A patent/AR079552A1/es unknown
- 2010-12-20 SG SG10201710751TA patent/SG10201710751TA/en unknown
- 2010-12-20 AP AP2012006331A patent/AP3536A/xx active
- 2010-12-20 EA EA201290451A patent/EA025445B1/ru not_active IP Right Cessation
- 2010-12-20 CN CN201410377525.7A patent/CN104147010A/zh active Pending
- 2010-12-20 PE PE2012000852A patent/PE20121520A1/es active IP Right Grant
- 2010-12-20 CN CN201510028705.9A patent/CN104688739A/zh active Pending
- 2010-12-20 HU HUE10798436A patent/HUE026916T2/en unknown
- 2010-12-20 RS RS20150489A patent/RS54118B1/en unknown
- 2010-12-20 AU AU2010339753A patent/AU2010339753B2/en not_active Ceased
- 2010-12-20 PL PL14161300T patent/PL2749282T3/pl unknown
- 2010-12-20 ES ES10798436.1T patent/ES2540093T3/es active Active
- 2010-12-20 EA EA201691336A patent/EA201691336A1/ru unknown
- 2010-12-20 SI SI201031571T patent/SI2749282T1/sl unknown
- 2010-12-20 PT PT107984361T patent/PT2515900E/pt unknown
- 2010-12-20 JP JP2012544937A patent/JP5723889B2/ja active Active
- 2010-12-20 EP EP14161300.0A patent/EP2749282B1/en active Active
- 2010-12-20 SG SG10201408528RA patent/SG10201408528RA/en unknown
- 2010-12-20 MX MX2014002642A patent/MX344329B/es unknown
- 2010-12-20 CA CA2784028A patent/CA2784028C/en not_active Expired - Fee Related
- 2010-12-20 UY UY33119A patent/UY33119A/xx not_active Application Discontinuation
- 2010-12-20 KR KR1020127018477A patent/KR20120107995A/ko active Application Filing
- 2010-12-20 PL PL10798436T patent/PL2515900T3/pl unknown
- 2010-12-20 US US12/972,949 patent/US8513254B2/en not_active Expired - Fee Related
- 2010-12-20 ES ES14161300.0T patent/ES2646603T3/es active Active
- 2010-12-20 KR KR1020167024642A patent/KR20160108611A/ko not_active Application Discontinuation
-
2012
- 2012-06-04 IL IL220152A patent/IL220152A/en not_active IP Right Cessation
- 2012-06-14 CL CL2012001597A patent/CL2012001597A1/es unknown
- 2012-06-21 ZA ZA2012/04608A patent/ZA201204608B/en unknown
- 2012-06-27 EC ECSP12012004 patent/ECSP12012004A/es unknown
- 2012-06-27 CR CR20120353A patent/CR20120353A/es not_active Application Discontinuation
- 2012-11-13 HK HK12111501.5A patent/HK1170675A1/xx not_active IP Right Cessation
-
2013
- 2013-05-31 US US13/907,349 patent/US8754087B2/en not_active Expired - Fee Related
-
2014
- 2014-03-20 US US14/221,014 patent/US9056108B2/en not_active Expired - Fee Related
- 2014-12-22 JP JP2014258433A patent/JP2015057449A/ja not_active Withdrawn
-
2015
- 2015-06-15 HR HRP20150644TT patent/HRP20150644T1/hr unknown
- 2015-07-14 SM SM201500171T patent/SMT201500171B/xx unknown
- 2015-07-17 CY CY20151100625T patent/CY1116511T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012015499A2 (pt) | método de tratamento de fibrilação atrial | |
ECSP12012002A (es) | Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería | |
BR112018002304A8 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
BR112017027798A2 (pt) | compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
MX2019012113A (es) | Terapia génica para la deficiencia de la aadc. | |
BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
BR112015006828A2 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar uma doença em um paciente em necessidade do tratamento; e método para modular a atividade de uma proteína ire1 | |
MX2010004508A (es) | Suministro de agentes activos. | |
BRPI0707235B1 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
BR112014015482A8 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
BR112012029959A2 (pt) | compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo | |
BR112015004902A2 (pt) | métodos e composição neutroprotetores anticolinérgicos | |
BR112012023139A2 (pt) | composição farmacêutica para a prevenção ou o tratamento de doença do fígado gordo não alcóolico e o método para a prevenção ou tratamento de doença do fígado gordo não alcóolico usando a mesma. | |
BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
BR112014023423A2 (pt) | terapia de combinação | |
BR112013018598A2 (pt) | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca | |
BR112014012054A2 (pt) | métodos de tratamento com deferiprona | |
BR112014002885A2 (pt) | uso de composto orgânico para o tratamento da síndrome de noonan | |
BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
BR112012020377A2 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
BR112013016615A2 (pt) | uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática | |
BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |